Skip to main content
curacle co., ltd. logo

curacle co., ltd. — Investor Relations & Filings

Ticker · 365270 ISIN · KR7365270008 KO Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2021-09-30 Board/Management Inform…
Country KR South Korea
Listing KO 365270

About curacle co., ltd.

http://www.curacle.com/eng/main/

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Recent filings

Filing Released Lang Actions
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of a co-CEO (Kim Myung-hwa) and the transition to a single CEO structure (Park Gwang-rak). It explicitly lists the change in management, the reason for the change, and the effective date. This falls directly under the definition of Board/Management Information (MANG).
2021-09-30 Korean
수시공시의무관련사항(공정공시)(대표이사 변경 예정에 관한 사항)
Board/Management Information Classification · 100% confidence The document is a regulatory disclosure regarding the planned change of the company's CEO (Representative Director). It explicitly details the outgoing and incoming directors and the reasons for the change. This falls directly under the category of announcements regarding changes in senior management.
2021-09-30 Korean
투자판단관련주요경영사항(당뇨병성 신증 치료제 CU01-1001의 식품의약품안전처 3상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean company Curacle regarding the submission of a Phase 3 clinical trial application (IND) for their drug CU01-1001 to the Ministry of Food and Drug Safety (MFDS). This is a specific corporate disclosure regarding material business developments, specifically related to clinical trial progress. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure of a material event, it is classified as a Regulatory Filing (RNS).
2021-09-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard South Korean regulatory disclosure form (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where company executives or major shareholders report changes in their shareholdings. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2021-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This is a standard regulatory filing used by insiders (executives/directors) to disclose their personal share transactions or changes in ownership. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers insider trades and ownership reports by company directors and executives.
2021-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). This is a standard regulatory filing in South Korea used by insiders (executives/major shareholders) to disclose their personal share transactions or changes in ownership. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2021-09-09 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.